Global Blood Therapeutics, Inc.
GBTNASDAQHealthcare
$68.49
+$0.01(+0.01%)
Market Cap$0
P/E Ratio—
52W High$73.02
52W Low$21.65
Global Blood Therapeutics, Inc. (GBT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GBT · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2022Report Date: Aug 8, 2022EPS Actual
-$1.26
Est. -$1.18 · -6.8%
Revenue
$0.07B
Fiscal Period
Q3 FY2022
FY ends December
Report Date
Aug 8, 2022
After Market Close
▼ Miss EPS
GBT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q4 FY2022 | Nov 2, 2022 | -$1.06 | — | — | — | $0.07B | — |
| ▼ Q3 FY2022 | Aug 8, 2022 | -$1.18 | -$1.26 | -6.8% | $0.07B | — | — |
| ▲ Q2 FY2022 | May 4, 2022 | -$1.30 | -$1.26 | +3.1% | $0.06B | $0.06B | -3.0% |
| ▼ Q1 FY2022 | Feb 23, 2022 | -$1.13 | -$1.36 | -20.4% | $0.06B | $0.06B | +1.9% |
| ▼ Q4 FY2021 | Nov 4, 2021 | -$1.11 | -$1.13 | -1.8% | $0.05B | $0.05B | -2.7% |
| ▲ Q3 FY2021 | Aug 3, 2021 | -$1.19 | -$1.12 | +5.9% | $0.05B | $0.04B | +8.3% |
| ▼ Q2 FY2021 | May 5, 2021 | -$1.01 | -$1.21 | -19.8% | $0.04B | $0.04B | -10.2% |
| ▼ Q1 FY2021 | Feb 24, 2021 | -$0.94 | -$1.00 | -6.4% | $0.04B | $0.04B | +4.5% |
Q4 FY2022
Nov 2, 2022
EPS Actual
—
EPS Est.
-$1.06
EPS Surpr.
—
Revenue
—
Q3 FY2022
Aug 8, 2022Miss
EPS Actual
-$1.26
EPS Est.
-$1.18
EPS Surpr.
-6.8%
Revenue
$0.07B
Q2 FY2022
May 4, 2022Beat
EPS Actual
-$1.26
EPS Est.
-$1.30
EPS Surpr.
+3.1%
Revenue
$0.06B
Q1 FY2022
Feb 23, 2022Miss
EPS Actual
-$1.36
EPS Est.
-$1.13
EPS Surpr.
-20.4%
Revenue
$0.06B
Q4 FY2021
Nov 4, 2021Miss
EPS Actual
-$1.13
EPS Est.
-$1.11
EPS Surpr.
-1.8%
Revenue
$0.05B
Q3 FY2021
Aug 3, 2021Beat
EPS Actual
-$1.12
EPS Est.
-$1.19
EPS Surpr.
+5.9%
Revenue
$0.05B
Q2 FY2021
May 5, 2021Miss
EPS Actual
-$1.21
EPS Est.
-$1.01
EPS Surpr.
-19.8%
Revenue
$0.04B
Q1 FY2021
Feb 24, 2021Miss
EPS Actual
-$1.00
EPS Est.
-$0.94
EPS Surpr.
-6.4%
Revenue
$0.04B
No analyst estimates available for GBT.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q3 FY2022 | Aug 8, 2022 | -6.8% | $63.84 | $66.60 | +4.32% |
| ▲ Q2 FY2022 | May 4, 2022 | +3.1% | $32.04 | $32.15 | +0.34% |
| ▼ Q1 FY2022 | Feb 23, 2022 | -20.4% | $31.22 | $28.78 | -7.82% |
| ▼ Q4 FY2021 | Nov 4, 2021 | -1.8% | $40.26 | $39.37 | -2.21% |
| ▲ Q3 FY2021 | Aug 3, 2021 | +5.9% | $27.75 | $26.89 | -3.10% |
| ▼ Q2 FY2021 | May 5, 2021 | -19.8% | $38.98 | $39.83 | +2.18% |
| ▼ Q1 FY2021 | Feb 24, 2021 | -6.4% | $48.03 | $49.19 | +2.42% |
| ▼ Q4 FY2020 | Nov 5, 2020 | -27.6% | $61.88 | $60.32 | -2.52% |
Q3 FY2022+4.32%
Report Date
Aug 8, 2022
EPS Beat/Miss
-6.8%
Price Before
$63.84
Price After
$66.60
Q2 FY2022+0.34%
Report Date
May 4, 2022
EPS Beat/Miss
+3.1%
Price Before
$32.04
Price After
$32.15
Q1 FY2022-7.82%
Report Date
Feb 23, 2022
EPS Beat/Miss
-20.4%
Price Before
$31.22
Price After
$28.78
Q4 FY2021-2.21%
Report Date
Nov 4, 2021
EPS Beat/Miss
-1.8%
Price Before
$40.26
Price After
$39.37
Q3 FY2021-3.10%
Report Date
Aug 3, 2021
EPS Beat/Miss
+5.9%
Price Before
$27.75
Price After
$26.89
Q2 FY2021+2.18%
Report Date
May 5, 2021
EPS Beat/Miss
-19.8%
Price Before
$38.98
Price After
$39.83
Q1 FY2021+2.42%
Report Date
Feb 24, 2021
EPS Beat/Miss
-6.4%
Price Before
$48.03
Price After
$49.19
Q4 FY2020-2.52%
Report Date
Nov 5, 2020
EPS Beat/Miss
-27.6%
Price Before
$61.88
Price After
$60.32
Avg Beat Reaction-1.38%
Avg Miss Reaction-0.60%
Beat Rate2 / 8 quarters
Largest Move-7.82% (Q1 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GBT ends December
Global Blood Therapeutics, Inc. (GBT) most recently reported earnings on August 8, 2022 for Q3 FY2022, posting EPS of $-1.26 — missing the analyst consensus of $-1.18 by -6.8%. The next GBT earnings date is expected around September 1, 2026.
Each quarter, investors track GBT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GBT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GBT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GBT earnings · 5 questionsGlobal Blood Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. GBT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GBT historically reports after market close (AMC).
GBT earnings datewhen is GBT earningsGBT next earnings datewhen does GBT report earningsGBT earnings calendar
▸ Source: FMP · Global Blood Therapeutics, Inc. SEC filings · US GAAP · Global Blood Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026